-
Xinghai Forum: Professors Yang Zhang and Kejing Zhang Discuss CDK4/6 Inhibitors in Adjuvant Therapy for HR+ Breast Cancer
Xinghai Forum: Professors Yang Zhang and Kejing Zhang Discuss CDK4/6 Inhibitors in Adjuvant Therapy for HR+ Breast Cancer Prognostic Value of ctDNA Testing in MonarchE Trial Patients and Its Value…
-
EHA 2024: Transforming Insights into Action for Better Patient Outcomes
As we reflect on EHA 2024, the impact of this year’s congress continues to resonate within the hematology community. The groundbreaking research, innovative treatment strategies, and expert discussions presented at…
-
EHA 2024: Pioneering Advances in Hematology and Innovative Therapies
The recent European Hematology Association (EHA) Congress highlighted crucial advancements in hematology, emphasizing the significance of cutting-edge research and its impact on clinical practices. This year’s sessions provided invaluable insights…
-
EHA 2024: Bridging Research and Practice to Elevate Hematology Care
From clinical trials to real-world applications, the EHA Congress has bridged the gap between research and practice, enhancing the standard of care for hematological patients. #EHA2024 #BridgingTheGap
-
Exciting Moments at EHA2024 Hybrid Congress in Madrid!
The European Hematology Association’s 2024 Hybrid Congress is underway in Madrid, bringing together experts and professionals from around the world. From insightful sessions to groundbreaking research, this event is set…
-
A Doctor’s Battle Against Cancer: A Story of Hope and Innovation
An extraordinary story that shines a light on the remarkable advances in cancer treatment and the power of innovative research.Professor Richard Scolyer, co-director of the Melanoma Institute Australia, was faced…
Connecting Medical Expertise through Media
